Inflammatory Bowel Disease (Ibd) Therapeutics Market- Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Inflammatory Bowel Disease (Ibd) Therapeutics Market- Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Inflammatory Bowel Disease (IBD) Therapeutics marketis projected to register a CAGR of 4.8% during the forecast period (2022-2027).

With the rise of COVID 19, there has been a rise in other complications that arise along with the infection. According to a report by Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database in January 2022, adverse COVID 19 outcomes were associated with the age and other co morbidities among patients with IBD. The novel severe acute respiratory syndrome - related corona virus, upon entering the gastrointestinal tract, initiates activation of innate and adaptive immune responses. The onset of inflammatory reactions can supposedly induce intestinal damage in IBD patients. Also, a research article by Monteleone G., published in Journal of Crohn’s and colitis in March 2020 showed that the IBD patients undertaking immune suppressors are associated with greater risk of infections, even though there are no evidence to suggest that the COVID affects IBD patients more commonly than the general population. As per a review article in World journal of Gastroenterology by Sultan K., in October 2020, it was comprehended that many COVID 19 patients were found to develop gastrointestinal complaints. Older IBD patients with co morbidities such as hypertension, coronary heart disease, diabetes mellitus and obstructive lung disease are more susceptible to COVID 19 infection, as indicated by Neurath MF in an article published in the journal, Gut in July 2020. Thus, there is an increasing demand for Inflammatory Bowel Disease (IBD) Therapeutics market to manage further complications that could develop due to COVID 19.

The increasing occurrence of Crohn’s disease and Ulcerative colitis is the major driver which is predicted to boost the growth of the market. According to a report by Center for Disease Control and Prevention (CDC) published in April 2021, on the World IBD Day (May 19), the number of people affected by IBD is around 7 million around the world. The report also stated that the rate of prevalence of the disease has significantly increased during the last two decades. The prevalence of chronic health conditions such as cancer, arthritis, migraine, and other cardiovascular, respiratory, kidney and liver diseases are higher in IBD patients than non IBD patients. In older population (>66 years old), patients with IBD were more susceptible to hospitalization for hip fractures. Also, they were found to have 30 day readmissions and longer hospital stays. Studies being done on the treatment of IBD for prevention of such instances are a great boost to the development of the market in the upcoming period.

Increase in the approval of biologics and the presence of robust pipeline products is expected to propel the growth of the market. As per a study by Alulis S., published in BMC Health Services Research journal in August 2021, the IBD patients receiving biologic treatments were found to have higher average annual healthcare costs. The increasing use of biologic therapies in IBD patients provides lucrative opportunities for market growth attributing to the vast costs of biologics. The improving demand for IBD medication is expected to drive the market growth. However, lack of awareness among people about IBD is expected to limit the growth of the market.

The Janus Kinase (JAK) inhibitors are a major fraction of the drug classes used in the treatment of IBD. A study by Rogler G published in Journal of Crohn’s and colitis in November 2019, showed that JAK inhibitors are an attractive treatment option for Crohn’s Disease and Ulcerative colitis. The newer classes of orally administered JAK inhibitors are being clinically tested.

As per above source, phase II studies are being conducted to study the efficacy of the JAK inhibitors, filgotinib and upadacitinib. Consequently phase III programmes for both the drugs have been initiated. The significance of the research on the JAK inhibitors places a special focus which could have a major impact on the growth of the market.

Recently, combination therapies are being studied as the crucial resource for the treatment of refractory IBD. As discussed in a article by Parigi TL published in Expert Review of Clinical Immunology in December 2021, JAK inhibitors in combination with other biologic treatment methods, have illustrated adequate safety profile and comparatively good efficacy.

Significant discoveries in the treatment of IBD, especially the use of biologics, is expected to increase the Inflammatory Bowel Disease (IBD) Therapeutics market. JAK inhinitors, often known as oral biologics, are antibodies that are synthesized in vivo, that act specifically by stopping certain inflammation causing proteins. There is a large importance placed on the research of using JAK inhibitors and the magnitude of the research work being done on further combination therapy is subtantial. These factors are expected to have a significant impact on the growth of the IBD treatment market in the upcoming period.

The regions of high income, specifically United States has been found to have the largest number of IBD cases reported. United States was found to have the highest age standardised prevaence rate among the world. A systemic analysis published in Lancet journal for Gastroenterology and Hepatology in October 2019 revealed that United States harboured about one fourth of the global IBD population. The increased awareness and advanced treatment rates account for the larger disposition of the disease in the North American region. The increase in the prescription rates of the innovative medicines is expected to drive the demand for the IBD therapeutics market in the North American region. Increase in research and development in the clinical stage companies in the novel treatments for the disease is predicted to boost the growth of IBD therapeutics market in the region. In a study by Alatab, as published in Lancet journal for Gastroenterology and Hepatology in January 2020, it was found that the prevalence of the disease ranged from 252 to 439 cases per 100,000 population in United States. There also has been an increase in the number of cases in the Asia Pacific, owing to rapid industrialization and improved awareness among the population. The Asia Pacific region, is expected to be fastest growing market due to larger consumer base and increasing approval of IBD therapeutics.

The Inflammatory Bowel Disease (IBD) Therapeutics market is fragmented competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Bristol-Myers Squibb Company, AbbVie Inc., Allergan Therapeutics LLC, Bausch Health Companies Inc. (Salix Pharmaceuticals), Rare Disease Therapeutics Inc., Johnson & Johnson Services Inc., Janssen Biotech, Inc., UCB Inc. and others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support